Professor Philippe Moreau brings 20 years of experience in clinical hematology Translational research head at University Hospital of Nantes, France World-renowned expert in multiple myeloma, leading clinical trials Joins US-based SAB members, Prof Malcolm Brenner MD, Ph.D. and Prof Jeffrey Miller MD Galway, Ireland, and San Diego, USA, 8 April 2021 – ONK Therapeutics Ltd, […]
License with NIH for intellectual property for a clinically-validated, GMP grade feeder cell line to enable robust natural killer (NK) cell expansion Enhances ONK Therapeutics’ evolving research efforts to scale up and support clinical trials Galway, Ireland, and San Diego, USA, 18 March 2021 – ONK Therapeutics Ltd, an innovative cell therapy company focused on […]
Anthony Nolan Cell & Gene Therapy Services will provide umbilical cord blood and cord-derived NK cells to facilitate the development of ONK Therapeutics’ next-generation dual-targeted NK cell therapies Collaboration supports a common mission to improve the lives of patients with hematological malignancies and solid tumors London, UK and Galway, Ireland, and San Diego, USA 22 […]
Mary Reilly joins as COO, to lead the company’s international operations and drive growth ambitions to transition from a pre-clinical to a clinical-stage company 30 years’ experience in all aspects of global drug development and company operations Prior experience as COO at Opsona Therapeuticsas well as at BioInvent International, Neuramedy, Elan Pharmaceuticals, and Taro Pharmaceuticals […]
US-based Hugh O’Dowd joins the Board as independent Non-executive Chairman Brings significant experience in commercialization of oncology drugs Led Neon Therapeutics, Inc. for four years through to its acquisition by BioNTech SE Twenty years of big pharma experience gained at Novartis, including as CCO of Novartis Oncology Galway, Ireland and San Diego, USA, 14 January […]
Three new exclusive option license agreements expand the depth and breadth of ONK’s pre-clinical pipeline A humanized scFv targeting CLEC12A licensed from Cellerant Therapeutics, creates a fourth pre-clinical program, ONKT104, for the treatment of acute myeloid leukemia (AML) A humanized scFv targeting a novel tumor-specific MUC1 glycopeptide epitope licensed from Glycotope GmbH, strengthens pre-clinical program […]
ONK opens US operations and becomes a resident of Johnson & Johnson Innovation JLABS @ San Diego Rohit Duggal Ph.D. appointed as Head of R&D, USA ONK Therapeutics, Inc. formed, to facilitate the expansion of operations in the USA, alongside its growing hub in Galway, Ireland Galway, Ireland and San Diego, USA, 12 November 2020 […]
The Irish Times – View full story
